If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksK3 Business Technology Group Regulatory News (KBT)

  • There is currently no data for KBT

Placing

14 Jul 2011 12:20

RNS Number : 4095K
K3 Business Technology Group PLC
14 July 2011
 



14 July 2011

AIM: KBT

K3 BUSINESS TECHNOLOGY GROUP PLC

("K3" or "the Company")

 

Placing

 

K3, which provides and supports Enterprise Resource Planning software, hosting and managed services to the supply chain industry, is pleased to announce a placing of 2,564,408 new ordinary shares of 25p each ("New Ordinary Shares") at a price of 205p per share (the "New Placing") with new and existing institutional investors. The New Placing, which was oversubscribed, has raised a total of approximately £5.3 million (before expenses).

 

The placing price of 205p per share represents a discount of approximately 5.5% to the closing mid market share price on 13 July 2011, being the last practicable date prior to the issue of this announcement. The New Placing is, inter alia, conditional on admission of the New Ordinary Shares to trading on AIM ("Admission").

 

The proceeds of the New Placing will be used to support K3's strategy of seeking acquisitions to maximise the growth opportunities available. The Company has an established track record in successfully acquiring and integrating complementary businesses and the Board continues to identify targets which will add contracted, recurring income as well as those which will further develop the Company's product offering.

 

In addition to the New Placing, 1,200,000 existing ordinary shares on behalf of Laxnes B.V. ("Laxnes") and 63,993 existing ordinary shares on behalf of an employee of the Company have been placed with new and existing shareholders (the "Secondary Placing") at 205p per share. Following the Secondary Placing, Laxnes no longer has a disclosable interest in K3.

 

The 2,564,408 New Ordinary Shares represent approximately 9.0% of K3's enlarged issued share capital. Application has been made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on 19 July 2011. The New Ordinary Shares will rank pari passu with the existing shares of the Company. Following this allotment the total issued share capital of the Company will increase to 28,472,163 ordinary shares.  Canaccord Genuity is acting as sole book runner in relation to both the New and Secondary Placings.

 

The Company is also pleased to announce it has further strengthened its cash resources for potential acquisitions, having agreed additional banking facilities with its existing bank, Barclays Bank PLC, to match the proceeds of the New Placing on a pound-for-pound basis.

 

Andy Makeham, Chief Executive of K3, commented, 

 

"We are delighted to have completed this placing with good support from both new and existing institutional shareholders. K3 has demonstrated its ability to deliver strong growth both organically and via acquisitions and we believe that the demand for shares in the placing reflects the exciting opportunities for further expansion.

 

With these funds in place, as well as the support of our bank, Barclays, K3 is well positioned to achieve its growth ambitions."

 

 For further information:

 

K3 Business Technology Group plc

Andy Makeham, Chief Executive

T: 0161 876 4498

David Bolton, Finance Director

Canaccord Genuity Limited (NOMAD)

Simon Bridges / Cameron Duncan

T: 020 7050 6500

Biddicks

Katie Tzouliadis / Sophie Lane

T: 020 3178 6378

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEBBGDRCBBBGBS
Date   Source Headline
29th Nov 20215:36 pmRNSDirector/PDMR Shareholding
22nd Nov 20214:43 pmRNSPDMR Announcement
15th Nov 20212:30 pmRNSDirector/PDMR Shareholding
10th Nov 20215:06 pmRNSPDMR Announcement
18th Oct 202112:48 pmRNSPDMR Announcement
4th Oct 20213:00 pmRNSPDMR Announcement
27th Sep 20212:03 pmRNSPDMR Announcement
22nd Sep 202111:02 amRNSPDMR Announcement
20th Sep 20217:00 amRNSSale of Sage Business for £1.68m cash
26th Jul 20217:00 amRNSInterim Results
1st Jul 202111:37 amRNSHolding(s) in Company
21st Jun 20214:00 pmRNSPDMR Announcement
18th Jun 20214:54 pmRNSMarket Price Share Option Scheme
14th Jun 20218:08 amRNSPDMR Announcement
2nd Jun 202111:45 amRNSHolding(s) in Company
1st Jun 202110:46 amRNSPDMR Announcement
19th May 20211:30 pmRNSResult of AGM
12th May 20215:57 pmRNSDirector/PDMR Share Purchase
5th May 20211:43 pmRNSPDMR Announcement
4th May 20212:52 pmRNSDirector/PDMR Share Purchase
23rd Apr 20217:00 amRNSNotice of AGM and Posting of Annual Report
9th Apr 20212:49 pmRNSHolding(s) in Company
9th Apr 20212:47 pmRNSHolding(s) in Company
9th Apr 20212:46 pmRNSHolding(s) in Company
6th Apr 20214:59 pmRNSPDMR Announcement
30th Mar 20217:30 amRNSLong Term Incentive Plan Option Scheme
30th Mar 20217:30 amRNSShareholder Loan Conversion
30th Mar 20217:00 amRNSFinal Results
30th Mar 20217:00 amRNSAppointment of Chief Executive Officer
5th Mar 20217:00 amRNSBoard Change
1st Mar 20213:54 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSSale of subsidiary
13th Nov 20207:00 amRNSLong Term Incentive Plan
12th Nov 20207:00 amRNSPDMR Announcement
2nd Nov 20207:00 amRNSTrading Update
28th Oct 20207:00 amRNSAppointment of Chairman
28th Aug 202011:05 amRNSResult of General Meeting
12th Aug 20207:57 amRNSPDMR Announcement
11th Aug 20204:41 pmRNSSecond Price Monitoring Extn
11th Aug 20204:36 pmRNSPrice Monitoring Extension
10th Aug 20204:03 pmRNSPDMR Announcement
4th Aug 20207:00 amRNSInterim Results
29th Jul 20205:25 pmRNSNotice of General Meeting & Posting Annual Report
27th Jul 20207:00 amRNSFinal Results
15th Jul 20203:15 pmRNSNotice of Results
22nd Jun 20207:00 amRNSNotice of Results
29th May 202012:11 pmRNSResult of AGM
29th May 20207:00 amRNSAGM and Notice of Results
5th May 20209:47 amRNSNotice of AGM
3rd Apr 20205:08 pmRNSPDMR Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.